Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated by Analysts at Craig Hallum

Craig Hallum began coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research note released on Friday, MarketBeat reports. The firm issued a buy rating and a $12.00 price objective on the stock.

Other analysts have also issued reports about the company. Rodman & Renshaw assumed coverage on Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. RODMAN&RENSHAW raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Eupraxia Pharmaceuticals Trading Up 2.8 %

Shares of Eupraxia Pharmaceuticals stock opened at $3.65 on Friday. The business’s fifty day simple moving average is $3.13 and its 200 day simple moving average is $2.90. The firm has a market capitalization of $130.12 million and a P/E ratio of -5.07. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.15.

Institutional Trading of Eupraxia Pharmaceuticals

Large investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth $31,000. Raymond James Financial Inc. purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth $37,000. Finally, Bank of Montreal Can grew its position in shares of Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after purchasing an additional 7,500 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.